Botanix Pharmaceuticals Ltd (Botanix) carries out the development of next generation therapeutic treatments. The company deals with the clinical research of serious skin diseases using advanced novel transdermal drug delivery system and novel therapeutic treatments. The company's products include four programs for the treatment of plaque psoriasis, moderate acne, mild acne and serious acne and atopic dermatitis in Phase I clinical trials to assess potential. It acquired license for novel transdermal drug delivery technology, Permetrex for delivering pharmaceuticals through the skin. The company is also carries out the manufacture of synthetic cannabinoids. Botanix is headquartered at North Perth, Western Australia, Australia.
Headquarters
Australia
Address
D2, 661 Newcastle Street, Leederville, Western Australia, 6007
Website
botanixpharma.com
Telephone
61 8 65552945
No of Employees
1
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BOT (ASX)
Revenue (2022)
$117,100
351.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
30.5%
(2022 vs 2021)
Market Cap*
$217.3M
Net Profit Margin (2022)
XYZ
84.6%
(2022 vs 2021)
* As of and is in US$
Botanix Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Sofpironium Bromide - Axillary Hyperhidrosis (Excessive Underarm Sweating) |
| BTX1503 – Moderate to Severe Acne |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with UpScriptHealth to provide the digital platform and telehealth services for the commercial launch of Sofdra. |
| 2023 | Contracts/Agreements | In July, the company entered into an amendment to its asset purchase agreement with Fresh Tracks Therapeutics, Inc. to acquire rights to milestone and earnout payments on net acquisition of sofpironium bromide. |
| 2022 | Acquisitions/Mergers/Takeovers | In May, the company acquired a novel dermatology asset known as Sofpironium Bromide, which has been developed to treat primary axillary hyperhidrosis. |
Competitor Comparison
| Key Parameters | Botanix Pharmaceuticals Ltd | Melodiol Global Health Ltd | Cann Group Ltd | Acrux Ltd | AusCann Group Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Leederville | Perth | Melbourne | Melbourne | Perth |
| State/Province | Western Australia | Western Australia | Victoria | Victoria | Western Australia |
| No. of Employees | 1 | - | 40 | 43 | 27 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vince Ippolito | Chairman | Executive Board | 2019 | - |
| William Bosch | Chief Scientific Officer; Director | Executive Board | - | - |
| Matthew Callahan | Director | Executive Board | 2016 | - |
| Howie McKibbon | Chief Executive Officer | Senior Management | 2023 | - |
| Graeme Morissey | Chief Financial Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer